{"id":470770,"date":"2021-04-05T08:33:31","date_gmt":"2021-04-05T12:33:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470770"},"modified":"2021-04-05T08:33:31","modified_gmt":"2021-04-05T12:33:31","slug":"anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/","title":{"rendered":"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SAN JOSE, Calif.<\/span>, <span class=\"xn-chron\">April 5, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3118327-1&amp;h=4264566376&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc.\" rel=\"nofollow noopener noreferrer\">Anixa Biosciences, Inc.<\/a> (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg\" title=\"Anixa Biosciences, Inc. (PRNewsfoto\/Anixa Biosciences, Inc.)\" alt=\"Anixa Biosciences, Inc. (PRNewsfoto\/Anixa Biosciences, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Anixa and OntoChem are seeking to develop an orally administrable, room-temperature stable, anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19.\u00a0 The partners have recently completed POC studies in a Syrian Hamster model of the Covid-19 disease.\u00a0 Two potential compounds were evaluated as well as Remdesivir. \u00a0Data showed that administration of the drugs to infected hamsters did not cause any noticeable adverse effects, and monitoring of weight and general animal behavior demonstrated comparable efficacy of both Anixa compounds as well as Remdesivir.\u00a0 Viral shedding data and autopsied lung inflammation analysis was inconclusive for all drugs tested, perhaps due to the animal model being inadequate for such data. <\/p>\n<p>Dr. <span class=\"xn-person\">Amit Kumar<\/span>, President and CEO of Anixa Biosciences, stated, &#8220;Based on the promising preliminary data in the animal study, we have made the decision to proceed to the next stage of drug development.\u00a0 We have chosen one compound around which we will perform combinatorial synthetic medicinal chemistry to evaluate whether we can increase potency and optimize pharmacokinetics.\u00a0 The most promising compounds will again be evaluated in both <i>in vitro<\/i> and <i>in vivo<\/i> studies.&#8221;<\/p>\n<p>&#8220;We expect this next phase of development to take roughly four to five months with another decision point at that time,&#8221; said Dr. <span class=\"xn-person\">Lutz Weber<\/span>, CEO of OntoChem.\u00a0 &#8220;We are pleased that our progress to date has been successful and we are looking forward to the next phase of development.&#8221;<\/p>\n<p>\n        <b>About Anixa Biosciences, Inc.<br \/><\/b>Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. \u00a0Anixa&#8217;s therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. \u00a0The company&#8217;s vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. \u00a0These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. \u00a0Anixa continually examines emerging technologies in complementary fields for further development and commercialization. \u00a0Additional information is available at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3118327-1&amp;h=1487648544&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=www.anixa.com\" rel=\"nofollow noopener noreferrer\">www.anixa.com<\/a>.<\/p>\n<p>\n        <b><br \/>\n          <i>Forward-Looking Statements:<\/i><br \/>\n        <\/b>\u00a0 Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. \u00a0Forward-looking statements are not statements of historical facts, but rather reflect Anixa&#8217;s current expectations concerning future events and results. \u00a0We generally use the words &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;likely,&#8221; &#8220;will&#8221; and similar expressions to identify forward-looking statements. \u00a0Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. \u00a0These risks, uncertainties and factors include, but are not limited to, those factors set forth in &#8220;Item 1A &#8211; Risk Factors&#8221; and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. \u00a0We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. \u00a0You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.<\/p>\n<p>Investor contact:<br \/><span class=\"xn-person\">Mike Catelani<\/span><br \/><a target=\"_blank\" href=\"mailto:mcatelani@anixa.com\" rel=\"nofollow noopener noreferrer\">mcatelani@anixa.com<\/a><br \/>408-708-9808<\/p>\n<p>Media contact:<br \/><span class=\"xn-person\">Sherry Ash<\/span><br \/><a target=\"_blank\" href=\"mailto:anixapress@gmail.com\" rel=\"nofollow noopener noreferrer\">anixapress@gmail.com<\/a><\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA31664&amp;sd=2021-04-05\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic-301261855.html\">http:\/\/www.prnewswire.com\/news-releases\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic-301261855.html<\/a><\/p>\n<p>SOURCE  Anixa Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA31664&amp;Transmission_Id=202104050830PR_NEWS_USPR_____LA31664&amp;DateId=20210405\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN JOSE, Calif., April 5, 2021 \/PRNewswire\/ &#8212;\u00a0Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19. Anixa and OntoChem are seeking to develop an orally administrable, room-temperature stable, anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19.\u00a0 The partners have recently completed POC studies in a Syrian Hamster model of the Covid-19 disease.\u00a0 Two potential compounds were evaluated as well as Remdesivir. \u00a0Data showed that administration of the drugs to infected hamsters did not cause any noticeable adverse effects, and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-470770","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN JOSE, Calif., April 5, 2021 \/PRNewswire\/ &#8212;\u00a0Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19. Anixa and OntoChem are seeking to develop an orally administrable, room-temperature stable, anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19.\u00a0 The partners have recently completed POC studies in a Syrian Hamster model of the Covid-19 disease.\u00a0 Two potential compounds were evaluated as well as Remdesivir. \u00a0Data showed that administration of the drugs to infected hamsters did not cause any noticeable adverse effects, and &hellip; Continue reading &quot;Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-05T12:33:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic\",\"datePublished\":\"2021-04-05T12:33:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/\"},\"wordCount\":671,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/602982\\\/ITUS_Corporation_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/\",\"name\":\"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/602982\\\/ITUS_Corporation_Logo.jpg\",\"datePublished\":\"2021-04-05T12:33:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/602982\\\/ITUS_Corporation_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/602982\\\/ITUS_Corporation_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/","og_locale":"en_US","og_type":"article","og_title":"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic - Market Newsdesk","og_description":"PR Newswire SAN JOSE, Calif., April 5, 2021 \/PRNewswire\/ &#8212;\u00a0Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19. Anixa and OntoChem are seeking to develop an orally administrable, room-temperature stable, anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19.\u00a0 The partners have recently completed POC studies in a Syrian Hamster model of the Covid-19 disease.\u00a0 Two potential compounds were evaluated as well as Remdesivir. \u00a0Data showed that administration of the drugs to infected hamsters did not cause any noticeable adverse effects, and &hellip; Continue reading \"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-05T12:33:31+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic","datePublished":"2021-04-05T12:33:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/"},"wordCount":671,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/","name":"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg","datePublished":"2021-04-05T12:33:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=470770"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470770\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=470770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=470770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=470770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}